loading...| Preferred Name |
Auranofin |
|
| Synonyms |
|
|
| Definitions |
An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C65242 |
|
| CAS_Registry |
34031-32-8 |
|
| CHEBI_ID |
CHEBI:2922 |
|
| Chemical_Formula |
C20H34AuO9PS |
|
| code |
C65242 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis, with anti-inflammatory and potential antineoplastic activities. Auranofin interacts with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore, this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing expression of immune factors involved in inflammation. TrxR, overexpressed in many cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin (Trx) and plays a central role in regulating cellular redox homeostasis. |
|
| Display_Name |
Auranofin |
|
| FDA_UNII_Code |
3H04W2810V |
|
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Auranofin |
|
| Legacy Concept Name |
Auranofin |
|
| Maps_To |
Auranofin |
|
| NCI_Drug_Dictionary_ID |
710355 |
|
| PDQ_Closed_Trial_Search_ID |
710355 |
|
| PDQ_Open_Trial_Search_ID |
710355 |
|
| Preferred_Name |
Auranofin |
|
| prefixIRI |
NCIT:C65242 |
|
| prefLabel |
Auranofin |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0699923 |
|
| subClassOf |